The gut barrier, intestinal microbiota, and liver disease: Molecular mechanisms and strategies to manage

Vista sencilla de ítem
dc.contributor.authorPlaza-Díaz J.
dc.contributor.authorSolís-Urra P.
dc.contributor.authorRodríguez-Rodríguez F.
dc.contributor.authorOlivares-Arancibia J.
dc.contributor.authorNavarro-Oliveros M.
dc.contributor.authorAbadía-Molina F.
dc.contributor.authorÁlvarez-Mercado A.I.
dc.date.accessioned2021-11-05T19:03:56Z
dc.date.available2021-11-05T19:03:56Z
dc.date.issued2020-11
dc.descriptionIndexación Scopuses
dc.description.abstractLiver disease encompasses pathologies as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcohol liver disease, hepatocellular carcinoma, viral hepatitis, and autoimmune hepatitis. Nowadays, underlying mechanisms associating gut permeability and liver disease development are not well understood, although evidence points to the involvement of intestinal microbiota and their metabolites. Animal studies have shown alterations in Toll-like receptor signaling related to the leaky gut syndrome by the action of bacterial lipopolysaccharide. In humans, modifications of the intestinal microbiota in intestinal permeability have also been related to liver disease. Some of these changes were observed in bacterial species belonging Roseburia, Streptococcus, and Rothia. Currently, numerous strategies to treat liver disease are being assessed. This review summarizes and discusses studies addressed to determine mechanisms associated with the microbiota able to alter the intestinal barrier complementing the progress and advancement of liver disease, as well as the main strategies under development to manage these pathologies. We highlight those approaches that have shown improvement in intestinal microbiota and barrier function, namely lifestyle changes (diet and physical activity) and probiotics intervention. Nevertheless, knowledge about how such modifications are beneficial is still limited and specific mechanisms involved are not clear. Thus, further in-vitro, animal, and human studies are needed. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.es
dc.description.urihttps://www.mdpi.com/1422-0067/21/21/8351
dc.identifier.citationInternational Journal of Molecular Sciences, Volume 21, Issue 21, Pages 1 - 221 November 2020 Article number 8351es
dc.identifier.doi10.3390/ijms21218351
dc.identifier.issn16616596
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/20778
dc.language.isoenes
dc.publisherMDPI AGes
dc.subjectLiver diseasees
dc.subjectIntestinal barrieres
dc.subjectIntestinal permeabilityes
dc.subjectMicrobiotaes
dc.subjectRuminococcaceaees
dc.subjectDysbiosises
dc.titleThe gut barrier, intestinal microbiota, and liver disease: Molecular mechanisms and strategies to managees
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Plaza_J_The_gut_2020.pdf
Tamaño:
800.77 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FEd - Artículos de Revista